DPA ( DrugBank: - )

5 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	1
6	パーキンソン病	2
13	多発性硬化症／視神経脊髄炎	5
85	特発性間質性肺炎	1
127	前頭側頭葉変性症	1

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02405403 (ClinicalTrials.gov)	March 2015	2/3/2015	Microglial Activation Role In ALS (MARIA)	Microglial Activation Role In ALS (MARIA)	Amyotrophic Lateral Sclerosis	Drug: [18F]DPA-714 PET	University Hospital, Tours	NULL	Withdrawn	18 Years	N/A	All	0	Early Phase 1	France

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03230526 (ClinicalTrials.gov)	April 16, 2018	18/7/2017	Identification of a Biomarker Predictive of Evolution of Parkinson Disease	Brain Microglial Activation in the Early Stage of the Parkinson's Disease: a Predictive Biomarker of the Evolution?	Parkinson Disease	Drug: [18F]DPA-714 PET scan	Nantes University Hospital	NULL	Recruiting	40 Years	67 Years	All	64	Phase 2	France
2	NCT03457493 (ClinicalTrials.gov)	March 22, 2018	23/2/2018	The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy	UAB Neuroinflammation in Parkinson's Disease - TSPO-PET Substudy	Parkinson Disease	Drug: DPA-714-PET/MRI	University of Alabama at Birmingham	NULL	Recruiting	30 Years	N/A	All	20	Phase 1/Phase 2	United States

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03759522 (ClinicalTrials.gov)	February 3, 2019	6/11/2018	Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.	Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.	Fibromyalgia;Chronic Fatigue Syndrome;Multiple Sclerosis;Healthy	Drug: DPA-714 PET/MRI	University of Alabama at Birmingham	NULL	Recruiting	18 Years	65 Years	All	120	Phase 1	United States
2	NCT03691077 (ClinicalTrials.gov)	November 11, 2018	28/9/2018	Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714	A Prospective Study Evaluating the Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in Multiple Sclerosis Using PET-MRI With 18F-DPA714	Multiple Sclerosis;Relapse;Primary Progressive Multiple Sclerosis	Drug: Ocrelizumab	Assistance Publique - Hôpitaux de Paris	Roche Pharma AG;Institut du Cerveau et de la Moelle épinière	Recruiting	18 Years	60 Years	All	51	Phase 3	France
3	EUCTR2017-004158-40-FR (EUCTR)	11/09/2018	04/07/2018	NA	A Prospective study evaluating the effect of ocrelizumab on brain innate immune Microglial cells Activation in Multiple Sclerosis using PET-MRI with 18F-DPA714 - INN-MS	Patients with Relapsing MS or primary progressive MS MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrevus INN or Proposed INN: ocrelizumab Other descriptive name: ocrelizumab	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	71	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	France
4	EUCTR2014-002547-17-NL (EUCTR)	18/12/2014	01/12/2014	Imaging of inflammation in the cortex of the brain in progressive MS patients	Grey matter microglial imaging with [18F]DPA-714 in progressive MS patients - [18F]DPA-714 PET in MS	Progressive multiple sclerosis, both primary and secondary progressive MedDRA version: 17.1;Level: PT;Classification code 10063401;Term: Primary progressive multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1;Classification code 10063400;Term: Secondary progressive multiple sclerosis;Classification code 10053395;Term: Progressive multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: [18F]DPA-714 INN or Proposed INN: [18F]DPA-714 Other descriptive name: [18F]DPA-714	VU University Medical Center	NULL	Not Recruiting			Female: yes Male: yes			Netherlands
5	NCT02305264 (ClinicalTrials.gov)	March 19, 2012	25/1/2013	Imaging of Intracerebral Inflammation in MS	Imaging of Intracerebral Inflammation in the Progressive Phase of Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive;Multiple Sclerosis, Primary Progressive	Drug: 18F-DPA-714 and 18F-FDG	Assistance Publique - Hôpitaux de Paris	NULL	Completed	18 Years	65 Years	All	61	N/A	France

先頭へ

85. 特発性間質性肺炎

臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04362644 (ClinicalTrials.gov)	December 8, 2020	2/3/2020	Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis	Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714	University of Alabama at Birmingham	NULL	Recruiting	40 Years	85 Years	All	10	Phase 1	United States

127. 前頭側頭葉変性症

臨床試験数 : 90 / 薬物数 : 87 - (DrugBank : 30) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 88

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-002672-12-NL (EUCTR)	11/12/2020	08/10/2020	Imaging of neuroinflammation in frontotemporal dementia by means of PET-MRI	Frontotemporal dementia Imaging of Neuroinflammation, Degeneration and Microglia-Related Effects - FIND-MORE	Frontotemporal dementia (FTD), including symptomatic patients and presymptomatic individuals with genetic mutations predisposing to FTD at a later stage in life.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: [18F]DPA-714 INN or Proposed INN: [18F]DPA-714 Other descriptive name: [18-F]DPA-714	Erasmus Medical Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	32	Phase 2	Netherlands

先頭へ